Industry Updates for the Psychedelics World | Page 5 of 35

Psychedelics News

Industry

11 Sep 2023

PurMinds Appoints Leading Drug Designer to Scientific Advisory Board

Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience....

By Microdose NewsDesk

Industry

8 Sep 2023

Microdose Partners with Concordia for 2023 Annual Summit in New York City

Microdose is partnering with Concordia for the 2023 Concordia Annual Summit, taking place September 18-20 in New York City....

By Microdose NewsDesk

Industry

7 Sep 2023

Awakn Life Sciences Submits Clinical Trial Application for Phase 3 Trial

Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder....

By Microdose NewsDesk

Industry

5 Sep 2023

Cybin Granted U.S. Patent for 5-MeO-DMT

The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

15 Aug 2023

Cybin Granted U.S. Patent For Psilocybin Program

Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041...

By Microdose NewsDesk

Industry

10 Aug 2023

First Professional Practice Guidelines Published for Psychedelic-Assisted Therapy

The American Psychedelic Practitioners Association (APPA) has released the first-ever set of professional practice guidelines for psychedelic-assisted therapy....

By Microdose NewsDesk

Breaking News, Industry

9 Aug 2023

atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)

Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine)....

By Microdose NewsDesk

Industry

8 Aug 2023

Filament Health Announces FDA Approval of Two Clinical Trials

FDA has approved two clinical trials studying the effects of PEX010, Filament's botanical psilocybin drug candidate....

By Microdose NewsDesk

Industry

8 Aug 2023

Algernon NeuroScience Announces Phase 2 DMT Stroke Study

Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result